Business Context and Reporting Period
This Form 6-K filing by Silynxcom Ltd. covers the month of April 2025, specifically reporting on the closing of an underwritten public offering on April 2, 2025. The Company, a foreign private issuer based in Netanya, Israel, executed the offering pursuant to a shelf registration statement on Form F-3 declared effective on March 7, 2025.
Key Financial Metrics
- Shares Issued: 1,290,000 ordinary shares.
- Offering Price: $2.25 per share.
- Net Proceeds: Approximately $2.7 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Over-Allotment Option: The underwriter (ThinkEquity LLC) holds a 45-day option to purchase up to 193,500 additional shares.
- Warrant Issuance: A concurrent private placement warrant for 74,175 shares at an exercise price of $2.8125 per share (5% of the offering size).
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions as this report focuses solely on the capital raise transaction.
Material Changes
The primary material change is the increase in outstanding ordinary shares and the influx of capital from the public offering. Additionally, the Company and its officers and directors have entered into a 90-day lock-up agreement, restricting the sale or disposal of securities held by them following the closing date.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes. No specific financial guidance or operational outlook was provided in this filing.
Risks and Contingencies: The filing references customary representations, warranties, and indemnification provisions within the Underwriting Agreement. The warrant issued to the underwriter is exercisable starting six months after the commencement of sales and expires five years thereafter.
Investor Verification Checklist
- Verify the final number of shares issued if the over-allotment option is exercised.
- Confirm the exact amount of net proceeds after final settlement of offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Monitor the Company's Form 20-F for the impact of this capital raise on future liquidity and working capital requirements.